Long term safety follow up, dosimetry and immunologic responses in patients enrolled on a phase I trial of intraperitoneal 212Pb labeled trastuzumab

Alvarez, Ronald

157
Long term safety follow up, dosimetry and immunologic responses in patients enrolled on a phase I trial of intraperitoneal 212Pb labeled trastuzumab

Sunday, March 29, 2015: 3:05 PM

Salon C-D (Hilton Chicago)

R. Meredith¹, J. Torgue², R. D. Alvarez¹, S. Shen¹, D. R. Fisher³, E. Banaga², P. Bunch¹ and J. M. Straughn Jr.¹
¹University of Alabama at Birmingham, Birmingham, AL, ²AREVA Med, Bethesda, MD, ³Dade Moeller Health Group, Richland, WA

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

157
Long term safety follow up, dosimetry and immunologic responses in patients enrolled on a phase I trial of intraperitoneal 212Pb labeled trastuzumab

157 Long term safety follow up, dosimetry and immunologic responses in patients enrolled on a phase I trial of intraperitoneal 212Pb labeled trastuzumab

157
Long term safety follow up, dosimetry and immunologic responses in patients enrolled on a phase I trial of intraperitoneal 212Pb labeled trastuzumab